Non-insulin-dependent diabetes mellitus is characterized by an increased rate of endogenous glucose production (EGP) [1] which is essentially due to an increased gluconeogenesis [2, 3] .
Summary Resting, post-absorptive endogenous glucose production (EGP), fractional gluconeogenesis and liver glycogen concentration were assessed in 6 lean and 5 obese non-diabetic subjects undergoing elective abdominal surgery. During the 2 days preceding these measurements, 0.3 g/day U- 13 C glucose had been added to their usual diet to label their endogenous glycogen stores. On the morning of day 3, EGP was measured with 6,6-2 H glucose. Their endogenous 13 C glycogen enrichment was calculated from 13 CO 2 and respiratory gas exchanges. Fractional gluconeogenesis was assessed as 1-( 13 C glucose/ 13 C glycogen) ⋅ 100. EGP was similar in lean subjects (113 ± 5 mg/min) and in obese subjects (111 ± 6). Fractional gluconeogenesis was higher in obese (59 ± 10 %) than in lean subjects (29 ± 8 %).
However, overall EGP remained constant due to a decrease in glycogenolysis. Since an increased gluconeogenesis and a decreased glycogenolysis may both contribute to increase liver glycogen concentration in obesity, hepatic glycogen concentrations were assessed in hepatic needle biopsies obtained during surgery. Hepatic glycogen concentrations were increased in obese patients (515 ± 38 mg/g protein) compared to lean subjects (308 ± 58, p < 0.05). It is concluded that in obese patients: a) fractional gluconeogenesis is increased; b) overall EGP is unchanged due to a proportional inhibition of glycogenolysis; c) liver glycogen concentration is increased. The aim of the present study was to measure, in lean and obese non-diabetic subjects, total glucose production and the relative contributions of gluconeogenesis and glycogenolysis to EGP. Since changes of glycogen synthesis and breakdown are likely to be involved in the regulation of EGP, liver glycogen concentration was measured in needle liver biopsies obtained during surgery.
Subjects and methods
Subjects. Six lean and five obese patients undergoing elective abdominal surgery took part in this study. Their age, sex, and anthropometric characteristics are shown in Table 1 . The experimental protocol was approved by the Institutional Review Board for Human Investigation of Lausanne University School of Medicine, and all patients provided an informed written consent.
Study design. Two days before the study, breath and blood samples were collected for determination of the natural enrichment in 13 C of breath CO 2 and plasma glucose. Subjects then ate their usual, unstandardized diet, but ingested 0.1 g uniformly labelled 13 C glucose (Isotec Inc, Miamisburg, Ohio, USA) mixed with a fruit juice with each of the three main meals. This procedure was aimed to label the endogenous glycogen stores with 13 C. On the evening preceding the experiment, the last meal was ingested before 18.00 hours; patients were thereafter admitted to the hospital, and an indwelling venous cannula was inserted into an antecubital vein of the forearm. Through the cannula a continuous infusion of 6,6-2 H glucose (Tracer Technologies, Sommerville, Mass., USA) was started at a rate of 60
⋅ from 22.00 hours until the end of the experiment. At 06.30 hours the next morning, a second venous cannula was inserted in a hand vein of the controlateral arm for blood sampling at 07.00 and 07.30 hours. This hand was placed in a thermostabilized box heated to 56°C to achieve partial arterialization of venous blood. This allowed determination of the enrichments of plasma deuterated and 13 C labelled glucose, and plasma concentrations of glucose, insulin, non-esterified fatty acids and glucagon. Between 07.00 and 07.30 hours a ventilated canopy was fitted over the head and around the shoulders of the patients to monitor respiratory gas exchanges. Two breath samples were also collected for determination of the enrichment in 13 C of CO 2 during this period. A urine collection was obtained between 22.00 and 07.00 hours for determination of urinary nitrogen excretion rate. Pre-operative medications (midazolam + morphine sulfate or atropine) were then administered, and patients were taken to the operating theatre 30 to 60 minutes after the end of these measurements. Anaesthesia was performed with the use of isoflurane, fentanyl and vecuronil bromide. Two needle biopsies of the right liver lobe were obtained at the beginning of the operation and were immediately stored in liquid nitrogen until further analysis.
Indirect calorimetry. Respiratory gas exchanges were monitored continuously by open circuit indirect calorimetry using a deltatrac (Datex II, Deltatrac Instruments, Helsinki, Finland). Energy expenditure, net glucose, fat and protein oxidation rates were calculated from respiratory gas exchanges and urinary nitrogen excretion [16] .
Isotope analysis. Breath samples were collected in evacuated, air tight glass tubes (Europa Scientific Inc., Crewe, UK). Breath 13 CO 2 isotope enrichment was determined by CF-IRMS on a Roboprep G/Tracermass (Europa Scientific Inc.). Breath CO 2 isotopic enrichment was calculated vs breath CO 2 obtained prior to labelled glucose ingestion.
Plasma glucose isotope enrichments were determined on neutral fractions of deproteinized plasma samples partially purified over sequential anion-cation exchange resins. Plasma 13 C glucose enrichment was measured by gas chromatography-isotope ratio mass spectometry and was expressed in atom percent excess (APE) after derivatization to pentacetyl glucose [17] . Plasma 6,6-2 H glucose was measured by gas chromatographymass spectrometry of pentacetyl glucose, using the electron impact mode and selective monitoring of m/z 242.1 and 244.1.
Plasma hormone and substrate concentrations. Plasma glucose was determined by the glucose oxidase method using a Beckman Glucose Analyzer (Beckman Instruments, Fullerton, Calif., USA). Plasma insulin (kit from Biodata, Guidonia Montecellio, Italy) and glucagon (kit from DPC, Los Angeles, Calif., USA) were determined by radioimmunoassay. Urinary nitrogen was measured by the method of Kjehldahl [18] . Plasma non-esterified fatty acid concentration was determined colorimetrically using a kit from WAKO (Freiburg, Germany).
Biopsy analysis. Liver biopsies were assayed for glycogen content according to Chan and Exton [19] . Samples (10-15 mg) were homogenized in a buffer containing EDTA 10 mmol/l, KF 50 mmol/l, and glycerol 30 %, pH 7.0, using a polytron. An aliquot of the homogenate was spotted on a ET31 Whatmann paper for glycogen determination. The protein concentration was determined on another aliquot [20] .
Calculations. EGP, i. e. total rate of glucose appearance, was calculated from plasma 6,6-2 H glucose isotopic enrichment, using Steele's steady-state equation [21] .
Fractional glycogenolysis and gluconeogenesis were calculated from breath 13 CO 2 , plasma 13 C glucose and respiratory gas exchanges. This calculation is based on the following assumptions. 13 C glucose administered with the diet on the 2 days preceding the measurements results in a substantial enrichment of endogenous glycogen while it does not affect enrichment of lipid or protein pools. As a result, in basal, post-absorptive conditions, oxidation of 13 C enriched, endogenous glycogen is the sole source of 13 CO 2 enrichment. In addition, net carbohydrate oxidation corresponds essentially to oxidation by peripheral tissues of glucose issued from endogenous glycogen hydrolysis. Only liver glycogenolysis contributes to systemic glucose. In addition, it is assumed that oxidation of muscle glycogen represents only a minor portion of net carbohydrate oxidation in resting post-absorptive conditions. This assumption is based on the report that the respiratory exchange ratio of resting muscle is about 0.8, and that skeletal muscle takes up a substantial amount of systemic glucose [22] . Calculation of the enrichment of endogenous glycogen in exercising healthy lean volunteers (i. e. a mixture of hepatic and skeletal muscle glycogen) has in addition been shown to be only 20 % lower than the value calculated under resting conditions in the same subjects [23] . As a consequence, CO 2 produced from the oxidation of glycogen-derived glucose has an enrichment in 13 C similar to that of hepatic glycogen. Labelled 13 CO 2 is diluted with unlabelled CO 2 produced from lipid and protein oxidation. Gluconeogenesis from glycerol or amino acids results in the production of unlabelled glucose with a natural, low 13 C abundance, the oxidation of which is included in net lipid and protein oxidations, respectively. This unlabelled neoformed glucose dilutes the labelled glucose originating from glycogen hydrolysis. 13 C glycogen enrichment and gluconeogenesis can then be calculated as described previously [24] : Fractional glycogenolysis (%) = 13 C glucose enrichment 13 C glycogen enrichment × 100
Fractional gluconeogenesis (%) = 100-fractional glycogenolysis.
Quantitative glycogenolysis or gluconeogenesis can then be obtained by multiplying fractional glycogenolysis or gluconeogenesis by EGP.
Statistical analysis
Results are expressed as mean ± SEM. Data obtained in obese and lean patients were compared using the Wilcoxon rank sum test.
Results
Hormones and substrates. Plasma insulin and glucagon concentrations tended to be higher in obese patients compared to lean control patients whereas plasma glucose and non-esterified fatty acid concentrations were similar between the two groups of subjects (Table 2 ).
Substrate oxidation rates. Respiratory quotient was lower in obese (0.78 ± 0.02) than in lean patients (0.84 ± 0.01, p < 0.05). Obese subjects had a decreased net carbohydrate oxidation (59 ± 19 mg/min) and an increased lipid oxidation (80 ± 8 mg/min) compared to lean subjects (carbohydrate oxidation: 101 ± 11 mg/min, lipid oxidation 55 ± 5 mg/min) (Fig. 1 ). Protein oxidation rates (25 ± 7 mg/min in obese vs 20 ± 2 in lean subjects) and energy expenditure (1.07 ± 0.06 kcal/min in obese vs 0.97 ± 0.02 in lean subjects) were not significantly different between the two groups of subjects.
EGP, gluconeogenesis and glycogenolysis. EGP was similar in the two groups of subjects (111 ± 6 mg/min Values are mean ± SEM Fig. 1 . Post-absorptive lipid and carbohydrate oxidation rates in lean ( ) and obese (R) subjects. *p < 0.05 in obese vs 113 ± 5 in lean subjects). Breath 13 CO 2 and plasma 13 C glucose enrichments tended to be lower and hepatic 13 C glycogen enrichment to be higher in obese patients compared to lean control subjects as shown in Table 3 .
Fractional gluconeogenesis was increased in obese patients (59 ± 10 %) compared to lean subjects (29 ± 8 %, p < 0.05) (Fig. 2) . Absolute rates of gluconeogenesis were increased in obese patients (67 ± 14 mg/min vs 34 ± 10 mg/min in lean patients), although the difference did not reach significance (p = 0.10). Absolute rates of glycogenolysis were suppressed in obese patients (44 ± 11 mg/min) compared to lean control subjects (79 ± 6 mg/min, p < 0.05).
Hepatic glycogen concentration. Analysis of liver biopsies revealed a significantly higher glycogen concentration in obese patients compared to lean control subjects (515 ± 38 vs 308 ± 58 mg/g protein respectively) (Fig. 3) .
Discussion
The methodology used in the present study to assess fractional rates of glycogenolysis and gluconeogenesis differs markedly from the methods previously used to quantitate gluconeogenesis [25, 26] . It assesses the contribution of glycogenolysis to overall EGP from the measurement of plasma 13 C glucose, and an indirect assessment of liver 13 C glycogen enrichment. Gluconeogenesis is then calculated as the difference between EGP and glycogenolysis. In these experiments, the 13 C enrichment of hepatic glycogen extracted from liver biopsies was also measured (data not shown). This calculated value of liver 13 C glycogen enrichment was substantially higher than the measured enrichment of the glycogen extracted from liver biopsies (0.020 ± (SD) 0.009 APE). This latter value was even lower than plasma 13 C glucose enrichment, which indicates that only a minor portion of hepatic glycogen was actually participating in glycogen turnover in these sedentary individuals. We postulate that only the peripheral portion of the glycogen molecules had incorporated labelled glycosyl unit, and that only this same portion of the molecule actively released glucose during the experiments. Using an identical protocol we have previously observed that the calculated 13 C glycogen enrichment remained constant in healthy individuals between hours 12 and 18 of a fast [27] . This observation corroborates that the portion of actively turning-over hepatic glycogen was homogeneously labelled. Although such data were not obtained in obese subjects, it appears very unlikely that inhomogeneous labelling of endogenous glycogen would have interfered with the present measurements performed over 30 to 60 min. periods.
This method provides estimates of the contribution of gluconeogenesis to endogenous glucose production which are somewhat higher than those previously reported using splanchnic catheterization or rate of labelled glucose synthesis during infusion of labelled gluconeogenic precursors in healthy subjects fasted overnight. Measures obtained using in vivo 13 C nuclear magnetic resonance spectroscopy [3] or 2 H glucose synthesis after 2 H 2 O administration [28] reported even higher rates of fractional gluconeogenesis [3] .
There is, however, a limitation to the present method which has to be emphasized. In the Cori and glucose-alanine cycles, plasma glucose (a mixture of labelled glucose originating from glycogen hydrolysis and of unlabelled glucose originating from gluconeogenesis) is taken up by peripheral tissues to be partly released as lactate or alanine, which have essentially the same enrichment as plasma glucose. Although part of the tracer will be lost to CO 2 when these counpounds undergo gluconeogenesis, this can be expected to affect only slightly overall plasma 13 C Table 3 . 13 C isotopic enrichment in lean and obese patients glucose enrichment. As a consequence, fractional gluconeogenesis will not account for the activity of these cycles. The amount of glucose produced from the cycling between plasma glucose and three carbon compounds has been reported to represent 3 to 30 % of glucose turnover in healthy subjects and up to 45 % in obese diabetic patients [29, 30] . In addition, it is possible that muscle glycogenolysis or adipose tissue lipolysis release labelled lactate and glycerol, which may also lead to an underestimation of gluconeogenesis with the present method. Compared to lean subjects, obese patients had a similar glucose production but a lower net carbohydrate oxidation, and therefore a higher non-oxidative glucose disposal. Since the cycling between plasma glucose and three carbon compounds is included in this non-oxidative glucose disposal, it is likely that gluconeogenesis was even somewhat more underestimated in obese patients than in lean subjects using this technique.
The major observation of this study is that obese non-diabetic patients have a twofold increase in fractional gluconeogenesis (59 ± 10 %) compared to lean control subjects (29 ± 8 %). The mechanisms responsible for this increased gluconeogenesis are not clearly established. A larger delivery of gluconeogenic substrates to the liver, a stimulation of gluconeogenic precursor uptake by liver cells, or an enhanced activity of gluconeogenic enzymes could all possibly be involved.
It has been reported that obese patients produce excessive amounts of gluconeogenic precursors. Glycerol production is increased in obesity [14] . Protein turnover rate and consequently free amino acid availability, is increased in obese patients [13] . Lactate has been also shown to be produced in excessive amounts by adipocytes of obese subjects [31] .
Although gluconeogenesis was increased in obese non-diabetic patients, overall endogenous glucose production was comparable to that observed in lean subjects. This indicates that the regulation of EGP observed in healthy subjects is unaltered in obesity. There is evidence in healthy humans that basal hepatic glucose production remains constant when gluconeogenesis is acutely increased by infusion of gluconeogenic precursors [4, 7, 10] . An inhibition of glycogenolysis, an inhibition of gluconeogenesis from substrates other than the infused precursor and a stimulation of hepatic glycogen synthesis have all been suggested to participate in this acute regulation of EGP. The present results clearly indicate that in obese patients, an increased gluconeogenesis from endogenous glucose precursors is compensated for by a suppression of glycogenolysis in order to keep overall glucose output in the normal range. The mechanism which signals for inhibition of glycogenolysis cannot be determined from the present data. It may be hypothesized that the increased blood insulin concentration of obese patients contributes to the decreased glycogenolysis. Alternatively, an increase in gluconeogenesis may lead to an increase in intracellular glucose-6-phosphate and free glucose concentrations, which will favour deactivation of glycogen phosphorylase.
There was a 67 % increase in average glycogen concentration in liver cells of obese patients compared to lean subjects. Some of the lean patients had localized cancer, but an extensive staging failed to detect any dissemination of the tumours; furthermore, no patient reported recent weight loss or signs of malnutrition. It is therefore unlikely that their condition was responsible for a decrease in hepatic glycogen. We also considered sex distribution in the two groups as a possible explanation for the observed difference in hepatic glycogen. It appears however unlikely, because hepatic glycogen content was higher in 3 lean males (504 mg/g protein on average) than in 3 females (280 mg/g protein on average). In contrast, we cannot discard the hypothesis that age difference may contribute to variations in hepatic glycogen content.
This increase in glycogen concentrations in the liver of obese patients may be secondary to the decreased glycogenolysis observed in these patients. Alternatively, it may be hypothesized that the increased glucose-6-phosphate produced by gluconeogenesis initially stimulated glycogen synthesis, as observed in healthy subjects when gluconeogenic precursors are acutely infused [10, 12] . The increased glycogen concentration may secondarily inhibit glycogen synthesis, leading to further changes in the intracellular concentrations of intermediary substrates, which may be responsible for inhibition of glycogenolysis.
Three of the lean patients underwent surgery because of malignancies, and their clinical condition may have been a confounding factor. Cancer patients, however, have been shown to have enhanced, not decreased hepatic gluconeogenesis [32] .
From these data, we conclude that obese non-diabetic patients have an increased fractional gluconeogenesis. Total hepatic glucose production, however, remains comparable to that observed in lean subjects due to a proportional reduction in glycogenolysis. The increased rate of gluconeogenesis and the suppression of glycogenolysis may both contribute to increase hepatic glycogen concentrations in these patients.
